The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Open accessAbstract
GPRC5D is an attractive target for immunotherapy of myeloma, and optimized GPRC5D-targeted CAR T cells eradicate myeloma xenografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GPRC5D (G protein-coupled receptor, class C, group 5, member D) is a G-protein-coupled orphan receptor that highly expressed in malignant bone marrow plasma cells from CD138+ MM patients. Its expression in normal tissues is primarily limited to the hair follicle region. Importantly, GPRC5D is expressed independently of BCMA, making it a promising target for multiple myeloma therapy [214, 215].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [214]
The cited source says what the claim attributes to it.
In the citing paper
“One such promising target is GPRC5D, which has shown independent expression from BCMA and has demonstrated excellent anti-tumor activity in MM models with BCMA loss.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [214]
In the citing paper
“GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high-risk myeloma. 13,14,16,19-21”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [16]
In the citing paper
“GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high-risk myeloma. 13,14,16,19-21”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [16]
In the citing paper
“Given the localized expression of GPRC5D in nail beds in mice, 15-17”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [16]
In the citing paper
“Given the localized expression of GPRC5D in nail beds in mice, 15-17 nail toxic effects are probably related to on-target talquetamab activity.”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,363
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D. A., Wu, G. S., Sussman, R. T., Lanauze, C. B., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,279
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 14×
“R. Gardner, D. Wu, S. Cherian, M. Fang, L.-A. Hanafi, O. Finney, H. Smithers, M. C. Jensen, S. R. Riddell, D. G. Maloney, C. J. Turtle, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.”
InfluentialBrudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 792
Ali, S. A., Shi, V., Marić, I., Wang, M. L., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler‐Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 776
Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L., Finney, O. C., Smithers, H. M., Jensen, M. C., Riddell, S. R., Maloney, D. G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665547 · Cited by 751
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W. M., Lee, D. W., Shah, N. N., Stetler‐Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 579
Hudecek, M., Sommermeyer, D., Kosasih, P. L., Silva-Benedict, A., Liu, L., Rader, C. M., Jensen, M. C., & Riddell, S. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0127 · Cited by 550
King, M. A., Covassin, L., Brehm, M. A., Racki, W. J., Pearson, T., Leif, J., Laning, J. C., Fodor, W. L., Foreman, O., Burzenski, L. M., et al. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03933.x · Cited by 389
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Laurent, S. A., Hoffmann, F. S., Kuhn, P.-H., Cheng, Q., Chu, Y., Schmidt-Supprian, M., Hauck, S. M., Schuh, E., Krumbholz, M., Rübsamen, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms8333 · Cited by 377
Paus, R., Nickoloff, B. J., & ITO, T. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.014 · Cited by 325
Gomes‐Silva, D., Mukherjee, M., Srinivasan, M., Krenciute, G., Dakhova, O., Zheng, Y., Cabral, J. M. S., Rooney, C. M., Orange, J. S., Brenner, M. K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.015 · Cited by 293
Fine-tuning the CAR spacer improves T-cell potency
Watanabe, N., Bajgain, P., Sukumaran, S., Ansari, S., Heslop, H. E., Rooney, C. M., Brenner, M. K., Leen, A. M., & Vera, J. F. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1253656 · Cited by 216
Endogenous Nur77 Is a Specific Indicator of Antigen Receptor Signaling in Human T and B Cells
Ashouri, J. F., & Weiss, A. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601301 · Cited by 203
Immune Privilege in Hair Growth
Westgate, G. E., Craggs, R. I., & Gibson, W. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12481002 · Cited by 132
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase
Santos, E. B., Yeh, R., Lee, J., Nikhamin, Y., Punzalan, B. J., Punzalan, B., Perle, K. L., Larson, S. M., Sadelain, M., & Brentjens, R. J. (2009) · Nature Medicine · doi:10.1038/nm.1930 · Cited by 132
Self-citationAtamaniuk, J., Gleiss, A., Porpaczy, E., Kainz, B., Grunt, T. W., Raderer, M., Hilgarth, B., Drach, J., Ludwig, H., Gisslinger, H., et al. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2012.02679.x · Cited by 128
Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS™ technology
Timmerman, P., Puijk, W. C., & Meloen, R. H. (2007) · Journal of Molecular Recognition · doi:10.1002/jmr.846 · Cited by 121
Smith, E. L., Stæhr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.016 · Cited by 119
Self-citationRobust isolation of malignant plasma cells in multiple myeloma
Frigyesi, I., Adolfsson, J., Ali, M., Christophersen, M. K., Johnsson, E., Turesson, I., Gullberg, U., Hansson, M., & Nilsson, B. (2014) · Blood · doi:10.1182/blood-2013-09-529800 · Cited by 116
Gao, Y., Wang, X., Yan, H., Zeng, J., Ma, S., Niu, Y., Zhou, G., Jiang, Y., & Chen, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151118 · Cited by 115
Self-citationThe RAIG Family Member, GPRC5D, Is Associated with Hard-Keratinized Structures
Inoue, S., Nambu, T., & Shimomura, T. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.12628.x · Cited by 114
Covassin, L., Laning, J. C., Abdi, R., Langevin, D. L., Phillips, N. E., Shultz, L. D., & Brehm, M. A. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04462.x · Cited by 97
Wang, X., Marr, A. K., Breitkopf, T., Leung, G., Hao, J., Wang, E., Kwong, N., Akhoundsadegh, N., Chen, L., Mui, A., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.368 · Cited by 62
Self-citationGPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells
Cohen, Y., Gutwein, O., Garach-Jehoshua, O., Bar-Haim, A., & Kornberg, A. (2013) · Hematology · doi:10.1179/1607845413y.0000000079 · Cited by 54
Concurrent and Independent Binding of Fcγ Receptors IIa and IIIb to Surface-Bound IgG
Williams, T. E., Nagarajan, S., Selvaraj, P., & Zhu, C. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76436-8 · Cited by 50
Lawson, M. A., Paton‐Hough, J., Evans, H., Walker, R. E., Harris, W., Dharshi, R., Snowden, J. A., & Chantry, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119546 · Cited by 40
Kim, Y.-J., Yoon, B., Han, K., & Park, B. C. (2017) · Annals of Dermatology · doi:10.5021/ad.2017.29.5.597 · Cited by 16
Flagged first, then by citations
1 of the 35 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- A. D. Cohen, A. L. Garfall, E. A. Stadtmauer, S. F. Lacey, E. Lancaster, D. T. Vogl, B. M. Weiss, D. E. Ambrose, A. M. Nelson, F. Chen, G. Plesa, I. Kulikovskaya, V. Gonzalez, M. Gupta, R. M. Young, K. Dengel, L. O’keefe, S. Le, C. Richardson, R. E. Isaacs, J. J. Melenhorst, B. L. Levine, C. H. June, M. C. Milone, Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood 130, 505 (2017).
Cited by
Sorted by citations
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,525
Self-citationClinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
Metadata
- Authors
- Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., Do, T., Pham, M. T., Brown, J. M., De Larrea, C. F., Olson, E., Peguero, E., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., Almo, S. C., Wendel, H.-G., Riviere, I., Liu, C., Sather, B., & Brentjens, R. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Sloan Kettering Institute, New York, NY 10065, USA.
- Eureka Therapeutics (United States) (US)
- Albert Einstein College of Medicine (US)
- Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Eureka Therapeutics, Emeryville, CA 94608, USA.
- Corresponding author
- Brentjens, Renier J.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-03-27
- Volume
- 11
- Issue
- 485
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC7508042
- OpenAlex
- W2923396001
- Cited by
- 391
- References
- 35
- Citations by year
- 2026: 31 · 2025: 55 · 2024: 79 · 2023: 68 · 2022: 46 · 2021: 55 · 2020: 42 · 2019: 14
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R01 CA198095, R01 HG008325)
- National Cancer Institute (P30 CA008748, U54 OD020355-01, PO1 CA190174-01, P01 CA059350, P30 CA013330, R01 CA138738-05)
- Multiple Myeloma Research Foundation
- American Society of Hematology
- Leukemia and Lymphoma Society
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- GPRC5D, multiple myeloma, CAR T-cell therapy, BCMA, scFv, phage display
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Antibody Specificity, Humans, Multiple Myeloma, RNA, Messenger, Gene Expression, Immunotherapy, Adoptive, Mice, SCID, Mice, Inbred NOD, Xenograft Model Antitumor Assays, Receptors, G-Protein-Coupled, Cell Line, Tumor, Mice, B-Cell Maturation Antigen, Single-Chain Antibodies, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
